Abstract
Introduction

14
The underlying genetic contribution to many complex diseases and traits has been investigated 15 with great success by genome-wide association studies (GWAS). Various approaches have been 16 developed to identify regions associated with individual diseases, and these have led to the 17 detection of thousands of variants associated with a spectrum of diseases. In particular, much 18 progress has been made in the genetics of immune mediated diseases (IMD), revealing a complex 19 pattern of shared and overlapping genetic etiology 1, 2 . 20
21
Fine mapping -the process of distinguishing causal genetic variants from their neighbours -is an 22 essential step to enable the design of functional assays required to understand the mechanism by 23 which the region impacts disease risk, but it is complicated by linkage disequilibrium (LD) 3 . The 24 problem is often approached through stepwise regression 4 which assumes that statistical inference 25 of the best joint model (i.e. a model with multiple causal SNPs) can be derived by starting with the 26 most significant SNP, then conditioning on this and adding the next most significant, continuing this 27 conditioning until no conditionally significant SNPs remain. It has been noted that the SNP with the 28 smallest p value need not be causal, especially if it is in LD with two causal SNPs. 5 Alternative 29
Bayesian fine mapping methods have been developed which use a stochastic search instead of 30 stepwise search [6] [7] [8] . Stepwise and stochastic search results may disagree 8 and although stochastic 31 search generally demonstrates improved accuracy 9 these techniques have not yet been widely 32
adopted. 33 34
Here, we systematically compare stepwise and stochastic approaches by application to dense 35 genotype data for six IMD. We aim to address, in particular, the frequency and causes of 36 disagreement between stochastic and stepwise search results. Our results show that stochastic 37 search solutions are more likely to be correct than stepwise search results when sample sizes are 38
Stochastic and stepwise search differences in 10% of regions 48 We systematically applied stepwise and stochastic search fine mapping to dense genotyping data 49 from ImmunoChip studies of six IMD: type 1 diabetes (T1D) 10 , multiple sclerosis (MS) 11 , 50 autoimmune thyroid disease (ATD) 12 , celiac disease (CEL) 13 , juvenile idiopathic arthritis (JIA) 14 and 51 rheumatoid arthritis (RA) 15 (sample sizes given in Supplementary Table 1) in 90 densely mapped 52 regions with at least one associated disease (Supplementary Table 2 ), 204 disease-region-cohort 53 combinations in total. Results are given in Supplementary Tables 3-4. For RA and CEL, we 54 performed parallel analyses in UK-only and UK+international samples ("iRA" and "iCEL", 55 respectively). 56 57 Note that, unlike stepwise search which produces a single best model, stochastic search results 58 are a posterior probability distribution across typically thousands of potential causal variant models. 59
To make these more interpretable, SNPs in high LD which meet the criteria of substitutability (see 60
Methods) were grouped. The identification of SNP groups is a feature of stochastic search -61 generally, SNPs in a group have high LD and similar evidence for association, such that a single 62 candidate causal variant is not statistically distinguishable within the group. In general we prefer to 63 consider posterior support for each SNP group ("gPP") when interpreting the stochastic search 64
results. 65 66
In all regions, the model preferred by stochastic search either had equal or better Bayesian 67
Information Criterion (BIC) and equal or larger number of variants compared to the model chosen 68 by stepwise search (Supplementary Fig. 1 ). For 16 regions (18 disease-region pairs) the stepwise 69 model was nested in that of stochastic search (treating SNPs in strong LD as equivalent; 70 Supplementary Table 5 ). In six regions (6 disease-region pairs) there appeared to be two separate 71 signals, both weak (2x10 -10 < p < 4x10 -6 ) with stochastic search posterior support fairly evenly 72 shared between the two SNP groups, and the SNP selected by stepwise search happened to fall in 73 the group with slightly less posterior support (Table 1) . In a further four regions (5 disease-region 74 pairs) we found non-nested stochastic/stepwise mismatches, which could not be explained simply. 75
76
Joint tagging of stochastic search models by stepwise SNPs
77
We investigated these five mismatch cases further, both mathematically and using simulation, 78 hypothesising that they may reflect cases where the SNP with smallest p value acts to tag both of 79 two distinct causal variants 16 . We walk through these results using the example of ATD in a 80 chromosome 10p region. Haplotype analysis, which estimates effects for all observed 81 combinations of alleles across these three SNPs, illustrates how the minor allele of stepwise 82 search-selected SNP rs706779 (group "J") tends to be carried together with the minor alleles of 83 stochastic search-selected SNPs rs61839660 (group "A") and rs11594656 (group "C") (Fig 1a) . 84
Considering the haplotypes formed from rs706779/J, rs61839660/A and rs11594656/C, we see 85 that while haplotypes carrying the rs706779:C allele in the presence of either rs61839660:T or 86 rs11594656:A (haplotypes CTT or CCA) are protective for ATD, a haplotype carrying rs706779:C 87 in combination with rs61839660:C and rs11594656:T (CCT, frequency 13%) is indistinguishable 88 from the common (susceptible) haplotype TCT (Fig. 1a, p=0 . 24) . 89 90 First, simulations showed that if the J model were true, both stepwise and stochastic search would 91 correctly identify it (Fig. 1b, Supplementary Table 6 ). In contrast, if the A+C model were true, 92 stepwise got "stuck" on J, while stochastic search moved from selecting J at lower sample sizes, to 93 A+C at higher sample sizes (Fig. 1b, Supplementary Table 7 , further examples in other 94 regions/diseases in Supplementary Tables [8] [9] [10] [11] . A small perturbation on the simulated effect 95 sizes for A+C led both methods to select C or A+C directly, indicating that the potential for joint 96 tagging was dependent on the combined effect sizes. 97 98 Second, we showed mathematically that there was a high probability of J having the smallest p 99 value when A and C were causal only when A and C had similar odds ratios; and that our 100 observed data fell within this region (Fig. 1c) . Again, a similar pattern was seen at all other 101 mismatch regions ( Supplementary Fig. 2 ). 102 and GUESSFM for ATD in region 10p-6030000-6220000. There are four common haplotypes. 105
Three carry the minor allele at the J SNP rs706799, but only those that also carry minor allele at A 106 or C show a significant effect on disease risk. ) or the average posterior 111 probabilities for each model for the stochastic search approach. Sample size (x axis) is the number 112 of cases and controls. c Assuming A and C are causal, this plot shows the probability that J has 113 the smallest p value as a function of the effect sizes (log odds ratios) at A and C. The estimated 114 effects for A and C from real data are shown by a point, and the simulations from b by "<" and ">" 115 for A<C and A>C conditions, respectively. Fq (%) Finally, we showed that the pattern of LD between three SNPs (two causal and a third tag), 119 together with MAF (minor allele frequency) and effect sizes, determine whether a tag SNP has the 120 smallest expected p value (Fig. 2a, Supplementary Note) . At the extremes of this pattern, there is a 121 non-zero probability that the tag model will be erroneously selected, even by a criterion such as 122 BIC which penalizes the larger model (Supplementary Note). While we cannot identify how many 123 cases of joint tagging may exist in our GWAS data because the causal variants are unknown, we 124 can quantify what proportion of 3 SNP LD matrices match this pattern under an assumption of 125 equal odds ratios at the causal variants. Doing so, we found that 20-40% of potential common 126 causal variant pairs (MAF>5%) had a potential joint tag, though this was highly variable across 127 regions (Fig 2b-c cause stepwise search to get "stuck" on the tag, whereas stochastic search will find both causal 151 variants, if the sample sizes are large enough. However, with smaller sample sizes, stochastic 152 search may also choose the tag, because small sample sizes may not contain enough information 153 to overcome the strong penalty that needs to be applied to more complex models to avoid over-154 fitting. Thus, joint tagging may potentially affect many more cases than the simple comparison of 155 stepwise and stochastic search results based on fixed sample sizes above identify. 156
157
Proposed method for multinomial fine mapping (MFM) of multiple diseases
158
We noticed a striking overlap between the fine mapping results for different diseases in these 159 regions, with 20 of 30 regions with two or more associated diseases showing evidence of overlap 160 ( Supplementary Fig. 3 ), consistent with previous reports of shared genetic etiology between the 161 diseases 2 which inspired the creation of the ImmunoChip. This motivated us to exploit the sharing 162 between diseases, by extending the stochastic search approach to jointly analyse multiple 163 diseases, borrowing information between them, to help overcome these sample size limitations. 164 We use a multinomial logistic regression framework which is the natural extension of the binomial 165 logistic model, in which each individual is assumed to belong to exactly one disease group or a 166 pooled group of controls shared between diseases. This formally accounts for the sharing of 167 controls between diseases in different studies. 168
169
We introduce the concept of "configurations" -sets of causal variant models for each disease, and 170
we borrow information between the diseases by means of a prior which upweights configurations 171 that share one or more causal variants between diseases by a factor ! (Fig. 3) . Such a parameter 172 is also used in colocalization analysis, with values ranging from 100 1, 17 to 1000 18 . In the case of 173 MFM, it may be easier to elicit a prior on the chance of any sharing in causal variants between a 174 pair of diseases, and we show in the Supplementary Information how this value can be used to 175 derive ! for two or more diseases. In all our simulations and analyses, we chose ! so that the prior 176 on any pair of diseases sharing at least one causal variant in a region where they are both 177 associated is 0.5 One obvious challenge for dealing with configurations, is that the number of models that needs to 190 be considered for each disease is already large, and the number of possible configurations is the 191 product of these. This implies that exponentially increased computational time and memory will be 192 required to evaluate all configurations, and to store these results. We provide solutions for both 193 challenges. First, we show the log Bayes factor for a multinomial model that simultaneously 194 considers all diseases can be approximated by a quantity that can be rapidly calculated -the sum 195 of the log Bayes factors for the corresponding logistic models for each individual disease and an 
MFM increases chance of selecting the correct model
216
We examined the performance of MFM by simulation. We found that when causal variants 217 overlapped between diseases, MFM was able to recover the correct models at smaller sample 218 sizes than individual disease analysis (Fig. 4a-b, Supplementary Tables 12, 13 ), i.e. sharing 219 information between diseases contributed to a gain in accuracy similar to increasing sample size 220 for each disease. When no causal variants were shared, multinomial and independent approaches 221 generally gave very similar results (Fig. 4c, Supplementary Table 14) , i.e. sharing information did 222 not tend to mislead as long as there were strong signals in each disease. In the case that one 223 disease had no associations in the region, the multinomial analysis results were very close to 224 independent stochastic search results for the associated disease ( 
MFM analysis of up to six IMD
241
We applied MFM to all 30 ImmunoChip regions with at least two associated diseases (complete 242 results in Extended Information and Supplementary Table 16 ). We identified seven regions for 243 which the top model by single disease stochastic search and MFM differed ( Table 2) . Four of these 244
were single SNP models under single disease analysis which moved to an alternative single SNP 245 in joint analysis. For three of these four, the difference was seen in analysis of a UK-only subset, 246 so that we could consider single-disease analysis of the UK+international data which included 247 more samples but used the more conventional analysis method as an "adjudicator". In all three 248 cases, this adjudicator matched the MFM analysis of the UK-only data, suggesting that UK single 249 disease analysis was limited by power, and that UK MFM analysis increased power, allowing 250 conclusions to be drawn that were consistent with those seen in a larger single disease analysis. (Table 3) . While we suggested G may tag E+H, MFM 265 maintains strongest support for G in ATD, although there is also posterior support for H in 266 combination with other groups (group marginal posterior probability of inclusion, gMPPI=0.60). A 267 previous attempt to fine map autoimmune disease association, by colocalization analysis of T1D, 268 RA and CEL (using the same UK data as here) came to similar conclusions, finding strong support 269 for E+H models for iRA and T1D and either G or E+G for CEL 1 . However, a more recent analysis 270 of T1D and RA, also in largely the same samples, identified a different pair of variants, rs3087243 271 (G) and rs117701653 (C) 19 for both diseases using an exhaustive search of all one and two SNP 272 models. 273
274
We compared the models suggested by all these studies across all diseases by BIC 275 (Supplementary Table 17 ) and using haplotype analysis ( and G+C 19 have similar BIC in our data for iRA and iCEL (Supplementary Table 17 ), but the 281 greater number of SNPs in the E and H groups mean that E+H encompasses many more possible 282 causal variant pairs and so has greater grouped posterior support. Additionally, individual E+H 283 models have a clearly better fit than G+C for T1D (Supplementary Table 17 Comparison of stepwise and stochastic search applied to simulated data. Causal variants were 295 simulated as follows: "G": single causal variant G, OR=0. ) or the average posterior probabilities for each model 299 for the stochastic search approach. Sample size (x axis) is the number of cases and controls. c 300 Assuming E and H are causal, this plot shows the probability that G has the smallest p value as a 301 function of the effect sizes (log odds ratios) at E and H. The estimated effects for E and H from 302 
MAF
(log scale) Our previous report of stochastic-stepwise mismatch focused on MS and T1D in the IL2RA region 8 . 310
We identified four groups of SNPs corresponding to four causal variants for T1D, with results 311 agreeing between stepwise and stochastic search + memory T cells 23, 24 , and 358 a recent allele-specific expression study has pinpointed the causal variant affecting mRNA 359 expression among the set as rs61839660 25 -notably the same variant identified in an IBD GWAS 360 of 67,852 individuals 26 and an eczema/dermatitis phenotype in a GWAS of thousands of 361 phenotypes for 337,000 samples in the UK Biobank 27 , supporting the notion that this SNP has a 362 common effect across multiple diseases that is missed in stepwise analysis of MS and ATD. We 363 note that the direction of effect for rs61839660 is opposite in IBD and eczema/dermatitis (risk allele 364 T) compared to T1D, MS, ATD and JIA 14 (risk allele C). We note also that the minor alleles of 365 there is appears to be an allelic imbalance in naive CD4 + T cells favouring the A versus susceptible 399 haplotype, which is the opposite direction to that observed with protection at D and could reflect an 400 anticipatory differentiation of naive T cells toward the memory lineage and its phenotype of 401 increased CD25 expression in A haplotype donors. However, it is not significant, and we did not 402 observe an increase in CD25 + naive T cells associated with the A haplotype in a previous study 23 . 403 404 Additionally, we identified four individuals, three of whom carry rare IL2RA haplotypes ( 
Discussion
434
Fine mapping is a general problem in statistical genetics, important in its own right and for 435 informing integrative downstream analyses 18, 28 . We have shown that there are candidate causal 436 SNP models for which stepwise regression does not converge to the correct solution, even as the 437 sample size grows, and described the constraints on LD that give rise to this joint tagging 438 phenomenon. In contrast, stochastic searches do tend to the correct solution as sample sizes 439 increase, and we propose they should be more widely adopted by those interested in fine mapping 440 GWAS results. However, even stochastic search methods are limited by existing sample sizes 441 when there are multiple causal variants in proximity, and may produce similar results to stepwise 442 methods when sample sizes are insufficient. 443
444
Our new method MFM borrows information across diseases and is thus related to, but distinct 445 from, methods which aim to assess whether two diseases share causal variant(s) in a region 18, 29 or 446 which fine map those variants conditional on evidence for shared causal variants 1 . We avoid 447 enforcing identity of causal SNPs or their effect sizes between different diseases, as in analysis of 448 an overarching disease phenotype (eg "autoimmune disease" 19 ). It is clear from our results that, 449 causal variants may differ between diseases in the same region and that, even when causal 450 variants are shared, effect sizes and even direction of effects may differ between diseases. While 451 we use individual level genotype data from IMD studies, the method could be adapted to summary 452 GWAS data with Bayes factors calculated using summary data 7 or applied to other collections of 453 diseases where causal variants may tend to be shared, such as psychiatric diseases 30 or 454 metabolic-related traits 31 . 455
456
One key result from our analysis is that sample sizes in the low tens of thousands may still not be 457 large enough to robustly fine map multiple causal variants. This motivates continued collection of 458 GWAS samples for diseases too infrequent to be found in large numbers in the Biobank style 459 datasets, and greater sharing of data between researchers working on related diseases to better 460 map the most likely genetic causal variants. A particular note of caution is raised by the genomic 461 locations where we find discrepancies between stochastic and stepwise results. These are almost 462 entirely those with the strongest biological prior for involvement in these diseases, and also those 463 with typically the strongest effects, and thus greatest power. We question whether these regions 464 are most likely to give rise to discrepancies because they harbour the largest numbers of potential 465 effects or whether, if we had access to much larger datasets, we would see similar discrepancies 466 . Code to perform 498 the simulations can be found in https://github.com/jennasimit/MFMextra. Causal variants were 499 selected within SNP groups for each disease model (see Supplementary Table 18 ) with various 500 OR relating the odds of disease in heterozygote carriers of the non-reference allele compared to 501 the homozygote reference allele. We assumed a multiplicative model throughout. 502
The SNPs belonging to the above-mentioned groups, as well as the lead SNPs for autoimmune 503 thyroid disease (ATD; rs706799), alopecia areata (AA; rs3118470), rheumatoid arthritis (RA; 504 rs10795791), and ulcerative colitis (UC; rs4147359) were extracted from the generated data for 505 analyses via stepwise regression and stochastic search; the lead SNP for multiple sclerosis forms 506 group B. For each replication a stepwise regression model was fit, adding SNPs to the model using 507 a p-value threshold of 1×10 -6 . To generate stochastic search results, we used GUESSFM Simulations -multiple traits 514 We adapted the HapGen2 simulation outlined above to simulate datasets for two case and one 515 control set; code is available in https://github.com/jennasimit/MFMextra. First we used HapGen2 to 516 generate a population of 100,000 individuals based on the CEU 1000 Genomes Phase 3 data. 517
Causal variants for each trait were randomly selected within particular SNP groups for a certain 518 disease model (see Supplementary Table 18 ); when the same SNP group contained a causal 519 variant for both diseases, one variant was selected from the group and set as causal for both 520 diseases. Logistic regression models with the selected causal variants and odds ratios (OR) were 521 then used to assign each individual as either a member of the controls, disease 1 cases, or 522 disease 2 cases until the desired number of individuals in each group was attained; let ORjk be the 523 odds ratio for causal variant j and disease k. The prevalence for both diseases was set to 0.1, as 524 our purpose is to generate cases and controls for method comparison. In particular, the following 525 steps were used to ascertain control/disease 1/disease 2 status, where xij is the number of non-526 reference alleles of variant i for individual j (i.e. genotype score), gj is the vector of genotype scores 527 for individual j, " # =log(0.1), and " %& =log(ORik) is the effect of causal variant i for disease k. were considered for N ranging from 1000 to 5000; each simulation setting had 100 replications. 551
We compared the independent stochastic search analyses of each disease with the multinomial 552 approach with upweighted sharing based on a range of target odds (i.e. prior odds of no sharing of 553 causal variants between one disease and any other disease). We focused on a target odds (TO) of 554 1, such that there is an equal probability of sharing to non-sharing. Results for a range of TO from 555 9 (no sharing more likely than sharing of causal variants) to 0.35 (sharing more likely than distinct 556 causal variants) are in Supplementary Tables 12-15 . 557
Mathematical predictions of SNP with minimum univariate p value 558 559
We used "sunbeam plots" to characterize how changing the odds ratio of two causal SNPs in a 560 model can change the probability that a third variant will have the minimum p-value (and hence be 561 selected first in any stepwise fine mapping algorithm). We utilized components of the simGWAS 562 package (http://github.com/chr1swallace/simGWAS) to calculate expected GWAS Z scores for any 563
given set of causal variants and their effect sizes, across those causal variants and their 564 neighbouring SNPs 35 . We considered the behaviour of Z scores at each of two nominated "causal" 565 variants (following Fig. 1 , let us refer to these variants as A and C) with a third SNP, not itself 566 causal, but potentially correlated with both A and C (in Fig. 1 , this is SNP J). For each of a range of 567 possible odds ratios, we computed which of the three SNPs had the smallest expected p-value, 568
and coloured that square of the grid correspondingly. When the log odds ratios of both A and C 569 were close to 0, then no SNP had a low p-value and it was not possible to find significant evidence 570 of disease association in the region. This section of the grid was coloured white. Superimposed 571 upon the grid is a point corresponding to the odds ratio we computed for A and C from the real 572 dataset. Code to produce these plots is at https://github.com/chr1swallace/MFM-573 paper/tree/master/sunbeams. 574
575
Fine mapping analyses of ImmunoChip-genotyped diseases 576 We collated individual genotype data generated using the ImmunoChip for a total of 61,641 577 individuals, formed of controls and six disease cohorts: MS (UK subset) 11 , T1D 10 , juvenile 578 idopathic arthritis (JIA, UK subset) 14 , celiac disease 13 , rheumatoid arthritis (RA) 15 and autoimmune 579 thyroid disease (ATD) 12 (Supplementary Table 1 ). All genome coordinates are from build GRCh37. 580
To ensure controls could be combined across datasets, we restricted analysis for the multinomial 581 model to UK samples, and used principal component analysis including 1000 Genomes data to 582 exclude 2 individuals who fell outside individual country clusters. Genotypes were compared 583 between datasets to ensure exclusion of duplicate samples. Data were split into subsets according 584 to the densely genotyped regions targeted by the ImmunoChip (Supplementary Table 2) and 585 imputed to 1000 Genomes phase 3 33 using SHAPEIT 36 and IMPUTE2
37
. Phased reference data 586 was downloaded from https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html. Country and 587 the first 4 principal components were included as covariates in all regressions to account for 588 population structure. SNPs were excluded if they had info scores < 0.3, certainty < 0.98, |Z| for 589 HWE > 4 in UK controls, MAF < 0.5% in UK controls, call rate < 0.99 in any case or control group, 590 or an absolute difference in "certain genotype" call rates between controls and any case group of > 591 5%. 592 593 Forward stepwise regression was performed using univariate logistic regressions across all SNPs 594 in the region. The SNP with the strongest association (smallest p value) was selected, then all two 595 SNP models containing the selected SNP and any other SNP were considered, and the process 596 repeated until no SNP could be added with a marginal p < 10 -6 . 597 598 Stochastic search fine mapping of single diseases was performed using GUESSFM 599 (http://github.com/chr1swallace/GUESSFM). Initial searches were performed after tagging at 600 r 2 <0.99 with an optimistic binomial prior for the number of causal variants per region with 601 expectation set at 3 to allow good mixing of the chains. Reanalysis of the expanded tag sets for 602 SNPs in models included in the model set with total posterior probability 0.99 was performed using 603 approximate Bayes factors and the more conservative prior expectation of 2 causal variants per 604 region using GUESSFM. GUESSFM results were combined using the methods proposed in this 605 paper, as implemented in the R package MFM (http://github.com/jennasimit/MFM). We set the 606 prior odds that two diseases shared any causal variants to 1 (ie a 50% probability that they share 607 none). For a number of diseases, d > 2, we set the prior that the diseases share no causal variants 608 to 0.5 √E4+ , where the exponent is the geometric mean of the exponents in the (nonsensical) 609 extremes 0.5 E4+ which assumes all diseases are independent and 0.5 which assumes all diseases 610 are completely dependent. 611
612
Code to perform these steps is available at https://github.com/chr1swallace/MFM-analysis. 613
SNP grouping
614
SNPs with marginal posterior probability of inclusion > 0.001 were grouped according to criteria of 615 substitutability -that one SNP could substitute for another in all models. We reasoned that this 616 meant SNPs would need to be in LD -high r 2 -and rarely selected together in models -i.e. model 617 selection correlation (r) should be negative. We hierarchically cluster SNPs within each disease 618 according to r 2 x sign(r) using complete linkage, and group SNPs by cutting the tree such that all 619
SNPs within a group must have pairwise r 2 > 0.5, pairwise r < 0, and marginal posterior probability 620 that both are included in a model was < 0.01. We then identify overlapping groups defined in 621 different diseases, and merge or split groups when they meet this criteria. The specific algorithm is 622 defined in the group.multi function in 623 https://github.com/chr1swallace/GUESSFM/blob/master/R/groups.R. 624
625
Haplotype analyses
626
Haplotype analyses were performed by first phasing the genotypes across selected SNPs using an 627 E-M algorithm and selecting 10 multiply imputed samples from the posterior (snphap, 628 https://github.com/chr1swallace/snphap). These samples were analysed in parallel and results 629 combined using standard multiple imputation functions in the R package MICE anonymously and confidentially. Allele-specific expression analysis was performed as described in 642 To phase the direction of effect from the four donors carrying rare IL2RA haplotypes (Fig. 7a, 7c) , 647 their haplotypes were compared to those found in the 1000 Genome Project CEU data to assess 648 the allele frequency of the ASE readout SNP (rs12244380, A or G), to predict which allele is most 649 likely to be carried. For donor 1, the E haplotype carries the G allele with frequency 73% whereas 650 the susceptible haplotype carries the A allele 60% of the time. and for all examples of the D haplotype lacking B carries the A allele of rs12244380 (7/7). Where 657 multiple assays were performed on the same donor, we retained those with the smallest standard 658 Tables   Table 1: Regions that have conflicting models selected by stepwise and stochastic search for at least one autoimmune disease. Each row summarizes results for a single region, defined by chromosome, start and end coordinates (hg19), with neighbouring or previously reported candidate gene names shown for orientation. Each stepwise search model consists of a single SNP and we also indicate which SNP group it belongs to, by a letter in front of the SNP rs ID; the SNP group size, p-value of the SNP, and stochastic search group posterior probability (GPP) are also given. Analogous information is given for stochastic search models and for 2-SNP models the joint p-values from these model are given. The LD column lists the r 2 between the stepwise SNP and the SNP(s) from the stochastic search model. (a) Model mean posterior probability (GUESSFM; stochastic search) and (b) Mean model selection probability (stepwise regression) for simulated data having causal variant G with OR=1.25. Data were simulated with the characteristics of the CTLA4 region and there were 100 replications. Sample sizes were N cases, N controls for N=1000 to 5000 and are listed by column. (a) Model mean posterior probability (GUESSFM; stochastic search) and (b) Mean model selection probability (stepwise regression) for simulated data having causal variant B with OR=0.8. Data were simulated with the characteristics of the IL2RA region and there were 100 replications. Sample sizes were N cases, N controls for N=1000 to 5000 and are listed by column. MFM was run at a range of target odds (TO; prior odds of no sharing of causal variants between one disease and any other disease) values to illustrate the impact of TO and with decreasing TO there is an increasing prior weight for sharing of variants; TO=null indicates no sharing and independent stochastic search analyses were run and TO=1 was the setting used in our MFM analyses. MFM is run at a range of target odds (TO; prior odds of no sharing of causal variants between one disease and any other disease) values to illustrate the impact of TO and with decreasing TO there is an increasing prior weight for sharing of variants; TO=null indicates no sharing and independent stochastic search analyses were run and TO=1 was the setting used in our MFM analyses. Table 16 : MFM results for all regions that met criteria for fine-mapping of at least one autoimmune disease. For each region, SNPs from each SNP group are listed, together with base pairs position (GRCh37/hg19 assembly), alleles, MAF in UK samples, and marginal posterior probability of inclusion from stochastic search, MFM, and MFM with international samples. At the first SNP in each group, the marginal group posterior probability of inclusion is listed in the Total column for each of these analyses.
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Supplementary Table 17:
Comparison of the BICs for CTLA4 SNP models fit to ATD, CEL, T1D, international-RA and international-CEL. Representative SNP models are fit from several group models and the BIC of the best fitting model for each disease is in bold. The posterior probability (PP) and group PP (GPP) are given for each SNP and SNP group model, with the highest GPP model in bold.
Supplementary Table 18 : Details of IL2RA stochastic search and MFM results for ATD, MS, T1D and RA-international (iRA) and the resulting SNP groups. SNPs within each SNP group are listed, together with their base pairs position (GRCh37/hg19 assembly), alleles and MAF (based on UK controls data). Previous SNP groups (Wallace et al. 2015) are nested within our new SNP groups and these matches are marked. For both stochastic search (SS) and MFM, the marginal posterior probability of inclusion (MPPi) is given for each SNP and disease and the SNP group marginal posterior probability (Total MPPi). For MFM, ATD, MS and T1D analyses are based on UK samples, as well as the inclusion of international controls (int.ATD, int.MS, int.T1D); international RA (iRA) analyses are included, but not RA (UK only) since it did not meet our finemapping criteria. Table 18 is listed for each participant that ASE was performed on. The genotypes are phased so that all the SNPs listed for allele 1 are on the same chromosome, and gives directionality for the ASE readout SNP rs12244380, which is in the 3'UTR of IL2RA. ASE was measured using targeted NGS and the counts from each allele of rs12244380 are provided with 3-4 technical replicates performed. The average of the technical replicates was used to calculate the allelic ratio. Some samples were tested multiple times and these are highlighted in green. The allelic ratio for the central memory CD4 + T cells and naive CD4 + T cells are calculated as the ratio of A to G alleles at the readout SNP, and then re-ordered based on phased haplotypes to match the direction shown as top:bottom in the cartoon haplotypes depicted Fig. 7a . Not all samples were tested with both naive and central memory CD4+ T cells due to cell number availability. The genomic DNA samples are included as a control showing there is no bias regardless of genotype and all are reported as the ratio of the A:G allele of rs12244380.
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